Ivan D. Horak

Medicine · Health Sciences

69h-index17.5kcitations442works0.22yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(93), Monoclonal and Polyclonal Antibodies Research(87), Immune Cell Function and Interaction(79), HER2/EGFR in Cancer Research(68), Immunotherapy and Immune Responses(53)

Publications442 total

ADAPTOR PROTEIN CIN85 POTENTIATES THE MOTILITY OF OSTEOSARCOMA CELLS
Biotechnologia Acta·2025Open Access
Gemcitabine, carboplatin, and Epstein–Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial
Annals of Oncology·2024· 10 citedOpen Access
Supplementary Figure S5 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S3 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S12 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S9 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S17 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S16 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S6 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S16 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Table S1 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S12 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S13 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S10 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Table S1 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S8 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S17 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S11 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Data from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
Supplementary Figure S4 from Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy
2024Open Access
page 1 of 23Next →

Frequent Co-authors

Klaus‐Peter Knobeloch(9), Jürgen Löhler(7), David M. Goldenberg(7), Hubert Schorle(6), Eva Horak(6), Rolf M. Zinkernagel(4), Puja Sapra(4), Virgie G. Shore(4), Sarah Shefer(4), Hans J. Hansen(4), Thomas M. Cardillo(4), Benjamin Sadlack(3), Thomas Holtschke(3), Jeffrey F. Waring(3), Martin F. Bachmann(3), E Rohde(3), Joseph B. Bolen(3), Alton B. Kremer(3), Lee M. Greenberger(3), G Salen(3)